Atlas Trials

Nivolumab in Patients With IDH-Mutant Gliomas With and Without Hypermutator Phenotype

Clinical trial NCT03718767 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT03718767
Sponsor
National Cancer Institute (NCI)
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
GliomaGlioblastomaHigh Grade GliomaLow Grade GliomaMalignant Glioma
Start date
2019-03-27
Primary completion
2024-11-05
Enrollment
62

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.